E3酶MG53通过降解环林D1抑制瘤生长
Meng Fang1,2, Hong-Kun Wu3,4, Yumeng Pei1,2
1State Key Laboratory of Membrane Biology, Institute of Molecular Medicine, College of Future Technology, Peking University, 100871, Beijing, China.
Signal transduction and targeted therapy
|July 6, 2023
概括
MG53通过促进细胞循环的关键调节者cyclin D1的降解来抑制癌症. 瘤中MG53的下调与循环D1增加和生存率降低相关,这表明MG53是潜在的癌症治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞循环规则 细胞循环规则
背景情况:
- 异常的环素D1表达是许多癌症的标志,驱动细胞周期的进展,并有助于治疗耐药性.
- 环素D1无化和降解的失调与癌症发病和治疗失败有关,特别是在CDK4/6抑制剂中.
研究的目的:
- 研究MG53在调节环林D1稳定性的作用及其对结肠直肠和胃癌的影响.
- 阐明MG53影响细胞周期进展和瘤生长的机制.
主要方法:
- 在患者瘤组织和正常邻近组织中分析MG53和cyclin D1表达.
- 在体外和体内实验评估MG53调制对细胞周期,增殖和瘤生长的影响.
- 机理学研究涉及到无处不在的测试,以确定MG53在循环素D1降解中的作用.
主要成果:
- 在超过80%的结肠直肠和胃瘤中,MG53的显著下调,与环林D1水平和患者存活率相反相关.
- MG53直接催化K48结合的环素D1的泛化,导致其降解和G1细胞周期停止.
- 在临床前模型中,MG53的过度表达抑制了癌细胞的增殖和瘤的生长,而MG53缺乏会加速癌症的进展.
结论:
- MG53通过促进循环素D1的降解,从而抑制细胞循环的进展,起到瘤抑制作用.
- MG53在调节环林D1循环中的作用为特征为失调环林D1的癌症提供了一种新的治疗策略.
- 向MG53可能为治疗现有疗法耐药的恶性瘤提供新的途径.
更多相关视频
10:09Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
8.3K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.4K
相关概念视频
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
01:23Negative Regulator Molecules
35.5K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.5K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
00:50Anaphase Promoting Complex
2.9K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.9K
02:15M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K